Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

21.7 (USD) • At close June 30, 2025
Bedrijfsnaam Catalyst Pharmaceuticals, Inc.
Symbool CPRX
Munteenheid USD
Prijs 21.7
Beurswaarde 2,646,857,500
Dividendpercentage 0%
52-weken bereik 14.97 - 26.58
Industrie Biotechnology
Sector Healthcare
CEO Mr. Patrick J. McEnany
Website https://www.catalystpharma.com

An error occurred while fetching data.

Over Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of

Vergelijkbare Aandelen

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

1.12 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

35.99 USD

DocGo Inc. logo

DocGo Inc.

DCGO

1.57 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

11.03 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

2.2 USD

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

2.59 USD

Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL

9.22 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)